Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing-Reference-Cited by-同舟云学术

Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing

Published:2020-06-30 Issue:1 Volume:60 Page:89-102
ISSN:0312-5963
Container-title:Clinical Pharmacokinetics
language:en
Short-container-title:Clin Pharmacokinet

Author:

Yin Anyue^ORCID,Ettaieb Madeleine H. T.^ORCID,Swen Jesse J.,van Deun Liselotte,Kerkhofs Thomas M. A.,van der Straaten Robert J. H. M.,Corssmit Eleonora P. M.,Gelderblom Hans,Kerstens Michiel N.,Feelders Richard A.,Eekhoff Marelise,Timmers Henri J. L. M.,D’Avolio Antonio,Cusato Jessica,Guchelaar Henk-Jan,Haak Harm R.,Moes Dirk Jan A. R.^ORCID

Funder

HRA Pharma

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/s40262-020-00913-y.pdf

Reference30 articles.

1. Paragliola RM, Torino F, Papi G, Locantore P, Pontecorvi A, Corsello SM. Role of mitotane in adrenocortical carcinoma—review and state of the art. Eur Endocrinol. 2018;14(2):62–6. https://doi.org/10.17925/EE.2018.14.2.62.

2. Moolenaar AJ, van Slooten H, van Seters AP, Smeenk D. Blood levels of o, p’-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol. 1981;7(1):51–4. https://doi.org/10.1007/bf00258213.

3. Arshad U, Taubert M, Kurlbaum M, Frechen S, Herterich S, Megerle F, et al. Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients. Eur J Endocrinol. 2018;179(5):287–97. https://doi.org/10.1530/EJE-18-0342.